<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811265</url>
  </required_header>
  <id_info>
    <org_study_id>PC001</org_study_id>
    <nct_id>NCT00811265</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of ExAblate MRgFUS for Prostate Cancer</brief_title>
  <official_title>Safety, Compatibility and Imaging Quality of ExAblate Prostate Applicator for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate safety, compatibility and imaging quality of the
      ExAblate MRgFUS system for prostate cancer, under simulated use conditions. No acoustic
      energy will be delivered and no focused ultrasound therapy will be performed. This is an
      imaging only study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>Throughout study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device compatibility with human anatomy</measure>
    <time_frame>During simulated device use</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR Imaging Quality</measure>
    <time_frame>During simulated device use</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Simulated ExAblate MRgFUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing simulated ExAblate MRgFUS device use</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate MRgFUS for prostate cancer</intervention_name>
    <description>Simulated use of ExAblate MRgFUS system</description>
    <arm_group_label>Simulated ExAblate MRgFUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of patients: up to 75 years.

          -  Men scheduled for radical prostatectomy due to prostate cancer.

          -  Patients who are able and willing to give consent and able to attend all study visits.

        Exclusion Criteria:

          -  Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted
             ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast
             agent (e.g. Gadolinium or Magnevist)

          -  Severely abnormal coagulation (INR&gt;1.5)

          -  Patients with unstable cardiac status including: unstable angina pectoris on
             medication, patients with documented myocardial infarction within six months of
             protocol entry, congestive heart failure requiring medication (other than diuretic),
             patients on anti-arrhythmic drugs, severe hypertension (diastolic BP &gt; 100 on
             medication), and patients with cardiac pacemakers

          -  Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

          -  Individuals who are not able or willing to tolerate the required prolonged stationary
             supine position during imaging (approximately 1 hrs.)

          -  Any rectal pathology preventing probe insertion, (as active proctitis, ulcerative
             colitis, fissure ani, diverticulitis, previous rectal surgery, IBD, etcâ€¦)

          -  Any spinal pathology that prohibits maintaining supine position for more then an hour

          -  Any previous radiation to the pelvis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Web page of clinical study Sponsor</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ExAblate MRgFUS</keyword>
  <keyword>Focused ultrasound</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Radical prostatectomy candidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

